WuXi Launches Mobile OncoWuXi, the World’s First App for Accessing Oncology Services

We are excited to announce that we have launched a mobile version of OncoWuXi, the first app in the world to allow researchers to access oncology models and data on the...

WuXi AppTec Acquires ResearchPoint Global to Better Enable Clinical Development Worldwide

We are pleased to announce that WuXi has acquired ResearchPoint Global (RPG), a U..S-based contract research organization (CRO) with expertise spanning across all major therapeutic areas. RPG will become a wholly-owned...

WuXi Global Forum – “Gateway to China” during JP Morgan Conference 2013

January 8, 2013 | Grand Hyatt San Francisco China is the world’s 3rd largest pharmaceutical market, 2nd largest economy, and 1st largest population with huge unmet medical needs. This special forum hosted...

WuXi NextCODE Raises $75 Million in Series B Financing to Accelerate Growth of Global...

WuXi would like to congratulate WuXi NextCODE for raising $75 million in Series B financing, led by the company's current investors Temasek and Yunfeng Capital. WuXi NextCODE will focus the use of proceeds...

The U.S. FDA Completed Pre-License Inspection (PLI) of WuXi Biologics CGMP Manufacturing Facilities for...

We are pleased to announce that the U.S. Food and Drug Administration has completed the Pre-License Inspection (PLI) of WuXi Biologics cGMP manufacturing facilities for production of TMB-355 (ibalizumab) with no...

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

INNOVATION THAT MATTERS

A Futuristic Biopharma Company Addressing Some of the World’s Biggest Health...

By Rich Soll, Senior Advisor, Strategic Initiatives at WuXi AppTec (@richsollwx) For the past few years, PureTech Health has been building a new R&D model for advancing breakthrough...